Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The integrase inhibitor has a high barrier to resistance, but it can fail if used alone or with partner drugs that are not fully active.
After two years on lenacapavir, people with advanced immune suppression experienced substantial gains in CD4 T cells.
The novel HIV capsid inhibitor also shows promise for previously untreated people.
Findings confirm that Trogarzo maintains viral load suppression for nearly 10 years.
Extended follow-up confirms that the long-acting monoclonal antibody works well for people with highly resistant HIV.
A series of antibody infusions suppressed HIV for up to four months without prompting the virus to develop resistance.
The World Health Organization has recommended updated treatment protocols to combat drug-resistant gonorrhea, chlamydia and syphilis.
The main goal of HIV treatment is to fully suppress the virus so that your routine viral load tests consistently come back undetectable.
Those with surpassed HIV who cut back on taking Atripla from daily to 3 times a week maintained an undetectable viral load for 6 months.
Levels of transmitted antiretroviral resistance are high among the HIV population in Washington, DC, but have fallen in recent years.
People treated for HIV in Switzerland have seen steadily falling rates of resistance to antiretrovirals (ARVs) since 1999.
Among people who fail HIV treatment, resistance to tenofovir is common, and the incidence of such acquired resistance is likely increasing.
Those who develop resistance to Truvada after contracting HIV shortly before or while taking PrEP do not maintain such resistance for long.
ViiV Healthcare’s integrase inhibitor Tivicay (dolutegravir) effectively fights HIV even when people have taken HIV meds before and have resis...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.